Urge your members of Congress to support continued medical research funding
The House of Representatives released legislation, titled
the “American Health Care Act,” to repeal the Affordable Care Act. As
written, ASH has serious concerns that this legislation will reduce overall
access to coverage and treatment and would greatly impact patients with
hematologic diseases and disorders.
Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations.
On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model. CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.
ASH is pleased to see the National Heart, Lung and Blood Institute’s (NHLBI) continuous support (RFA-HL-15-030) for the development of improved techniques to enhance the production of clinically relevant, functional stem cell-derived red blood cells or platelets.
The American Society of Hematology (ASH) is committed to addressing the burden of sickle cell disease (SCD) and is undertaking a multifaceted initiative to improve outcomes for individuals with
the disease, both in the United States and globally.
A list of the highlights from ASH's 2016 advocacy campaigns focused on Physician Payment.
During 2016 ASH increased our advocacy efforts to ensure patients have access to safe hematologic drugs.
During 2016, ASH has continued to be one of the most visible advocates for federal support of biomedical research and funding for the National Institutes of Health (NIH) and took the following actions.
ASH recently submitted comments to the National Institute of General Medical Sciences (NIGMS) in response to a Request for Information on The Need for and Support of Research Resources for the Biomedical Research Community. ASH’s comments were developed based on the “ASH Agenda for Hematology Research” and input from members of the ASH Committee on Scientific Affairs and the ASH Scientific Committees. The Society’s recommendations call for dedicated funding and educational resources for advanced computational and biostatistical methods that will be crucial in accelerating progress in hematology research. ASH’s comments specifically mentioned genetics, epigenetics, gene therapies, immunotherapy, stem cell and regenerative medicine as areas that could benefit from these efforts.
On October 14, 2016, the Centers for Medicare and Medicaid Services (CMS) released its final rule implementing the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), signed into law on April 16, 2015. This summary looks at the MACRA Final Rule and the implications of it.
Support the mission of ASH and help move hematology forward.
Join the Grassroots Network to stay up to date on all of ASH’s Advocacy Campaigns.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology